Welcome to our dedicated page for UNITEDHEALTH GROUP SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UNITEDHEALTH GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UNITEDHEALTH GROUP's regulatory disclosures and financial reporting.
UnitedHealth Group’s Chief Accounting Officer Dennis Andrew Stankiewicz reported a small equity-related acquisition through a Form 4. He received 50.590 shares of common stock as dividend equivalents on outstanding restricted stock units, at a stated price of $0.00 per share.
These dividend equivalents are subject to the same vesting and forfeiture terms as the underlying restricted stock units. Following this award, his directly held common stock position reported in the filing increased to 10,256.529 shares, indicating a routine, compensation-linked update rather than an open-market transaction.
Baker Charles D. reported acquisition or exercise transactions in this Form 4 filing.
UNITEDHEALTH GROUP INC director Charles D. Baker received 13 shares of common stock as dividend equivalents on vested deferred stock units. These dividend-equivalent shares are immediately vested and carry the same terms as the underlying deferred stock units. Following this compensation-related award, Baker directly holds 2,176 shares of UnitedHealth Group common stock.
UNITEDHEALTH GROUP INC director Frederick William McNabb III received a grant tied to existing deferred stock units. On this Form 4, he acquired 50 shares of Common Stock at a price of $0.00 per share as dividend equivalents on vested deferred stock units. After this award, he directly holds 15,212 shares of UnitedHealth Group common stock. The dividend equivalents are immediately vested and are subject to the same terms as the underlying deferred stock units.
UNITEDHEALTH GROUP INC director Timothy Patrick Flynn reported routine equity compensation activity. He acquired 61 shares of Common Stock at $0.0000 per share as a grant or award on June 23, 2026. A footnote explains these represent dividend equivalents paid on vested deferred stock units, which are immediately vested and follow the same terms as the underlying units.
After this award, Flynn directly holds 10,650 shares of Common Stock and indirectly holds 6,033 shares through a trust. The filing reflects compensation-related share accruals rather than any open-market buying or selling.
UnitedHealth Group executive Patrick Hugh Conway, Chief Executive Officer of Optum, reported a tax-related share disposition. On June 5, 2026, 686.861 shares of common stock were withheld at $399.47 per share to cover tax obligations, leaving him with 16,914.309 directly held shares.
UnitedHealth Group Incorporated reported the results of its 2026 Annual Meeting of Shareholders. A total of 768,066,717 shares of common stock were represented. Shareholders elected nine directors for one-year terms, with support levels generally above 89% of votes cast for each nominee.
Shareholders approved, on a non-binding basis, the Company’s executive compensation, with 559,434,838 votes for and 82.74% of votes cast in favor. They also ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 95.00% of votes cast in favor. A shareholder proposal to require any board chair to be independent received 20.24% support and was not approved.
UnitedHealth Group executive Christopher R. Zaetta reported a small, routine tax-related share disposition. On this Form 4, he used 134.02 shares of UnitedHealth Group common stock, valued at $377.00 per share, to satisfy tax obligations. After this tax-withholding disposition, he continues to hold 16,582.149 shares directly, indicating the transaction affects only a minor portion of his overall position and does not represent an open-market sale.
UNITEDHEALTH GROUP executive Patrick Hugh Conway, Chief Executive Officer of Optum, used company shares to cover tax obligations on equity compensation. A total of 203.821 shares of common stock were disposed of at $377.92 per share, leaving him with 17,601.17 shares held directly.
UnitedHealth Group Incorporated plans to participate in the Bank of America Securities Health Care Conference 2026. Senior leaders will answer questions in an interview-style session covering the company’s strategy, market positions, recent results and expectations for its end markets.
The session is scheduled for May 12, 2026, beginning at 11:00 a.m. Eastern Time, and a live audio webcast will be accessible through the Investor Relations page on the company’s website. The disclosure is furnished under Regulation FD and is not deemed filed or incorporated by reference into other securities law filings unless specifically referenced.
UnitedHealth Group reported Q1 2026 results with modest growth and stable profitability. Total revenues were $111,721 million, up 2% year over year, while net earnings were $6,481 million and diluted EPS was $6.90, roughly in line with 2025.
UnitedHealthcare revenues rose 2% to $86,265 million, but medical membership fell by 1.1 million people, mainly in Medicare Advantage, Medicaid and commercial risk-based products. Optum revenues were flat at $63,749 million and earnings from operations declined 15% as value-based care businesses faced elevated medical cost trends and Medicare funding pressure.
The medical care ratio improved to 83.9% from 84.8% on favorable reserve development and affordability initiatives, while the operating cost ratio increased to 13.8% due to investments and restructuring. Cash flows from operations were strong at $8,912 million. The company executed portfolio divestitures, is exiting South American operations, plans about $3.0 billion of pending acquisitions, entered forward share repurchase contracts up to $2.0 billion, and received IRS Notices of Proposed Adjustment for 2017–2020 transfer pricing, which it intends to contest.